论文部分内容阅读
目的:研究舒利迭联合沐舒坦对稳定期慢阻肺疾病治疗的效果。方法:2013年2月--2014年2月在本院选取稳定期慢阻肺患者80例,并随机分为研究组40例、对照组40例,两组同时使用基础治疗方法,即给予解痉、平喘等对症处理,在基础治疗的基础上,研究组同时给予舒利迭联合沐舒坦进行治疗,两组的治疗周期都为10周,观察对比两组患者治疗前和治疗后的临床治疗效。结果:两组患者的治疗后效果具有明显的差异,P<0.05差异具有统计学意义。结论:舒利迭联合沐舒坦在治疗稳定期慢阻肺时,临床治疗效果明显,对改善患者的临床症状和体征以及肺功能等都有明显效果,建议临床推广。
Objective: To study the effect of seretide plus mucosolvan on the treatment of stable chronic obstructive pulmonary disease. Methods: From February 2013 to February 2014, 80 patients with stable chronic obstructive pulmonary disease (COPD) were selected in this study. They were randomly divided into study group 40 cases and control group 40 cases. The two groups were given basic treatment at the same time, Spasm, asthma and other symptomatic treatment, based on the basis of treatment, the study group also given seretide combined with ambroxol treatment, the two groups of treatment cycles were 10 weeks, the observed two groups of patients before and after treatment of clinical Therapeutic effect. Results: The two groups of patients after treatment with significant differences in the effect, P <0.05 difference was statistically significant. Conclusion: The combination of seretide and ambroxol in the treatment of chronic obstructive pulmonary disease, the clinical effect is obvious, to improve patients with clinical symptoms and signs and pulmonary function have a significant effect, it is recommended clinical promotion.